Tumour cell‐derived complement proteins, such as C3, which inherently inhibit anti‐tumour immunity, could potentially serve as effective targets for cancer immunotherapy, enhancing the anti‐tumour immune capabilities of the complement system. The gene discussed is VTN; the disease is cancer.